Chemexpress(SH:688131) Shang Hai Zheng Quan Bao·2025-04-18 22:34Core Viewpoint - The annual general meeting of Shanghai Haoyuan Pharmaceutical Co., Ltd. was held on April 18, 2025, where all proposed resolutions were approved without any objections [2][5][6]. Meeting Details - The meeting took place at the company's conference room located at 1999 Zhangheng Road, Pudong New District, Shanghai [2]. - A total of 205,266,769 shares with voting rights were present at the meeting, excluding shares held in the employee stock ownership plan [2]. - The meeting was chaired by Director Gao Qiang, as Chairman Zheng Baofu attended via telecommunication [3][4]. Resolutions Passed - The following key resolutions were approved: - 2024 Annual Board Work Report [5] - 2024 Independent Director Work Report [6] - 2024 Supervisory Board Work Report [6] - 2024 Annual Report and Summary [6] - 2024 Financial Settlement Report [6] - 2025 Financial Budget Report [6] - Reappointment of the auditing firm for 2025 [6] - 2025 Director Remuneration [6] - 2025 Supervisor Remuneration [7] - 2025 Expected Daily Related Transactions [7] - 2024 Profit Distribution Plan [7] - 2025 Mid-Year Dividend Arrangement [7] - Performance Commitment and Compensation Plan for Yaoyuan Pharmaceutical [7] - Authorization for the Board to handle related matters for performance compensation share buyback [7]. Legal Compliance - The meeting's procedures and voting methods were confirmed to comply with the Company Law, Securities Law, and the company's articles of association [3][11]. - The legal representatives from Shanghai Guangfa Law Firm confirmed the legality and validity of the meeting and its resolutions [11]. Convertible Bond Information - The company plans to issue convertible bonds totaling 822.35 million yuan, with a net amount of 811.74 million yuan after deducting issuance costs [14][15]. - The bonds will be convertible into shares starting from June 4, 2025 [17]. - Investors must meet the suitability requirements for investing in the Sci-Tech Innovation Board to convert the bonds into shares [18]. Share Buyback Announcement - The company will repurchase and cancel 47,725 shares due to unmet performance commitments, reducing the total shares from 210,959,781 to 210,912,056 [23]. - Creditors are notified of the capital reduction and have the right to claim debts within specified timeframes [24].